September 26, 2007 – Alkermes, Inc. (NASDAQ: ALKS) and Indevus Pharmaceuticals, Inc. (NASDAQ: IDEV) announced positive preliminary results from a randomized, double-blind, placebo controlled phase 2a clinical study of ALKS 27 in patients with chronic obstructive pulmonary disease (COPD).Alkermes' Press Release -
Indevus' Press Release -
